Compare JMM & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMM | ICCC |
|---|---|---|
| Founded | 1988 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 55.5M |
| IPO Year | N/A | 1987 |
| Metric | JMM | ICCC |
|---|---|---|
| Price | $6.08 | $5.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 18.8K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $27,769,304.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $21.23 |
| Revenue Growth | N/A | ★ 16.49 |
| 52 Week Low | $5.29 | $4.28 |
| 52 Week High | $6.10 | $7.60 |
| Indicator | JMM | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 53.46 |
| Support Level | $6.06 | $4.72 |
| Resistance Level | $6.15 | $5.36 |
| Average True Range (ATR) | 0.04 | 0.31 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 14.29 | 77.73 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.